Latest Product Launches News

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Integrated Research Limited reported a modest revenue dip and significant profit declines in FY25 as it pivots to a product-led growth strategy focused on AI-powered observability solutions and hybrid pricing models.

The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.

Gentrack Group reported a strong FY25 with revenue up 8% and net profit more than doubling, driven by key deployments of its new g2.0 cloud platform and robust growth in its airports division Veovo.

OMG Group has secured its maiden purchase order for premium SANDAI matcha in Australia, marking a promising start to a new high-margin revenue channel ahead of FY26.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

Spacetalk Ltd reveals a successful pivot to a software-led, hardware-enabled model, reporting 12% revenue growth and expanding into 15 international markets. The company targets $20–25 million in recurring revenue for 2026, underpinned by new product launches and strategic telco partnerships.

ReNerve Limited has raised $3.2 million through a two-tranche share placement to accelerate its sales and marketing efforts in the US and support upcoming product launches, including a new nerve conduit range.

Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.